Amidst ongoing discussions surrounding the potential adverse effects associated with the Covishield vaccine, Bharat Biotech has proactively released a statement to reaffirm the stringent safety and efficacy measures undertaken during the development of their COVID-19 vaccine. The company is resolute in its adherence to rigorous scientific protocols and regulatory standards throughout the vaccine’s development and evaluation process.
According to the statement, Bharat Biotech has employed a comprehensive approach to ensure the safety and efficacy of their COVID-19 vaccine. This approach encompasses meticulous preclinical studies, large-scale clinical trials involving diverse populations, and ongoing monitoring of vaccine performance post-authorization.
The company emphasizes that their vaccine has undergone rigorous assessment by independent regulatory bodies, including the Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organization (CDSCO). These evaluations have consistently demonstrated the vaccine’s safety and efficacy in preventing severe COVID-19 disease and reducing mortality rates.
Bharat Biotech has also established a robust pharmacovigilance system to monitor the safety of their COVID-19 vaccine in real-time. This system enables the company to promptly identify and investigate any potential adverse events associated with the vaccine, ensuring that appropriate measures can be taken to address any concerns.
Through their unwavering commitment to scientific rigor and regulatory compliance, Bharat Biotech aims to instill confidence in the safety and efficacy of their COVID-19 vaccine. The company’s proactive approach to addressing safety concerns underscores its dedication to protecting public health and contributing to the global fight against the COVID-19 pandemic.
